Data Insights

Lifirafenib maleate by BeiGene for Solid Tumor: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Data Insights

Lifirafenib maleate by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Data Insights

Lifirafenib maleate by BeiGene for Ovarian Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Data Insights

Lifirafenib maleate by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lifirafenib Maleate in Non-Small Cell Lung Cancer

Data Insights

Lifirafenib maleate by BeiGene for Endometrial Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lifirafenib Maleate in Endometrial Cancer

Data Insights

Lifirafenib maleate by BeiGene for Pancreatic Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

Lifirafenib maleate by BeiGene for Melanoma: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Melanoma. According to GlobalData, Phase II...

Data Insights

Lifirafenib maleate by BeiGene for Colorectal Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Data Insights

Lifirafenib maleate by BeiGene for Ovarian Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lifirafenib Maleate in Ovarian Cancer

Data Insights

Lifirafenib maleate by BeiGene for Thyroid Cancer: Likelihood of Approval

Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase...